Cannabics Pharmaceuticals Inc logo

CNBX - Cannabics Pharmaceuticals Inc Share Price

$0.191 -0.0  -5.3%

Last Trade - 06/08/20

Sector
Healthcare
Size
Micro Cap
Market Cap £20.8m
Enterprise Value £19.7m
Revenue £5.35k
Position in Universe 5120th / 6357
Bullish
Bearish
Unlock CNBX Revenue
Momentum
Relative Strength (%)
1m -15.7%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -66.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Aug 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.11 0.006 0.010 0.010
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 31 May 2020, Cannabics Pharmaceuticals Inc revenues decreased 36% to $5K. Net loss applicable to common stockholders totaled $6.7M vs. income of $2.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Research and development expense increase of 20% to $1.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CNBX Revenue Unlock CNBX Revenue

Net Income

CNBX Net Income Unlock CNBX Revenue

Normalised EPS

CNBX Normalised EPS Unlock CNBX Revenue

PE Ratio Range

CNBX PE Ratio Range Unlock CNBX Revenue

Dividend Yield Range

CNBX Dividend Yield Range Unlock CNBX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CNBX EPS Forecasts Unlock CNBX Revenue
Profile Summary

Cannabics Pharmaceuticals Inc., formerly American Mining Company, is a biotechnology pharmaceutical company. The Company is engaged in pharmaceutical development. The Company is focused on development and licensing of cannabinoid-based treatments and therapies. It develops and markets various therapies and biotechnological tools aimed at providing relief from ailments that respond to active ingredients sourced from the cannabis plant. These tools include delivery systems for cannabinoids, personalized medicine therapies and procedures based on cannabis originated compounds, and bioinformatics tools. The Company's flagship product is CANNABICS SR. CANNABICS SR is a technology for a long acting oil capsule that provides administration of cannabis. CANNABICS SR is composed solely from food grade materials and delivers effects for over 10 to 12 hours. The delivery method enables a once per day dosing regimen of medical cannabis to patients. It has not generated revenues.

Directors
Last Annual August 31st, 2019
Last Interim May 31st, 2020
Incorporated September 15, 2004
Public Since November 12, 2002
No. of Shareholders: 76
No. of Employees: 11
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OTC Markets Group
Shares in Issue 135,080,441
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CNBX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CNBX
Upcoming Events for CNBX
Frequently Asked Questions for Cannabics Pharmaceuticals Inc
What is the Cannabics Pharmaceuticals Inc share price?

As of 06/08/20, shares in Cannabics Pharmaceuticals Inc are trading at $0.191, giving the company a market capitalisation of £20.8m. This share price information is delayed by 15 minutes.

How has the Cannabics Pharmaceuticals Inc share price performed this year?

Shares in Cannabics Pharmaceuticals Inc are currently trading at $0.191 and the price has moved by -25.46% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cannabics Pharmaceuticals Inc price has moved by -32.18% over the past year.

What are the analyst and broker recommendations for Cannabics Pharmaceuticals Inc?

There are no analysts currently covering Cannabics Pharmaceuticals Inc.

When will Cannabics Pharmaceuticals Inc next release its financial results?

Cannabics Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-05-31
What is the Cannabics Pharmaceuticals Inc dividend yield?

Cannabics Pharmaceuticals Inc does not currently pay a dividend.

Does Cannabics Pharmaceuticals Inc pay a dividend?

Cannabics Pharmaceuticals Inc does not currently pay a dividend.

When does Cannabics Pharmaceuticals Inc next pay dividends?

Cannabics Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Cannabics Pharmaceuticals Inc shares?

To buy shares in Cannabics Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cannabics Pharmaceuticals Inc?

Shares in Cannabics Pharmaceuticals Inc are currently trading at $0.191, giving the company a market capitalisation of £20.8m.

Where are Cannabics Pharmaceuticals Inc shares listed? Where are Cannabics Pharmaceuticals Inc shares listed?

Here are the trading details for Cannabics Pharmaceuticals Inc:

Country of listing: United States
Exchange: OTC
Ticker Symbol: CNBX
What kind of share is Cannabics Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Cannabics Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cannabics Pharmaceuticals Inc share price forecast 2020?

We were not able to load any forecast data for Cannabics Pharmaceuticals Inc.

How can I tell whether the Cannabics Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cannabics Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -45.8%. At the current price of $0.191, shares in Cannabics Pharmaceuticals Inc are trading at -15.74% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cannabics Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Cannabics Pharmaceuticals Inc.

Who are the key directors of Cannabics Pharmaceuticals Inc?

Cannabics Pharmaceuticals Inc's management team is headed by:

Eyal Ballan - OTH
Itamar Borochov - DRC
Uri Ben-Or - CFO
Eyal Barad - CEO
Yasha Borstein - OTH
Gabriel Yariv - DRC
Who are the major shareholders of Cannabics Pharmaceuticals Inc?

Here are the top five shareholders of Cannabics Pharmaceuticals Inc based on the size of their shareholding:

Cannabics, Inc. Corporation
Percentage owned: 65.36% (88.3m shares)
Sabby Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 0.01% (7.29k shares)
Kirtchuk (Ariel) Individual Investor
Percentage owned: % (25 shares)
Barad (Eyal) Individual Investor
Percentage owned: % (0.316k shares)
Borochov (Itamar) Individual Investor
Percentage owned: % (0.222k shares)
Similar to CNBX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.